Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 13NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Gastrointestinal 1

Conditions

Breast Neoplasms 213Carcinoma, Non-Small-Cell Lung 148Lung Neoplasms 128Lymphoma 119Prostatic Neoplasms 115Leukemia 102Ovarian Neoplasms 100Central Nervous System Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Colorectal Neoplasms 89Head and Neck Neoplasms 87Sarcoma 84Multiple Myeloma 80Squamous Cell Carcinoma of Head and Neck 73Rectal Neoplasms 62Leukemia, Myeloid, Acute 62Carcinoma, Ovarian Epithelial 61Uterine Cervical Neoplasms 60Neoplasm Metastasis 59Brain Neoplasms 57Colonic Neoplasms 56Fallopian Tube Neoplasms 53Astrocytoma 53Lymphoma, Large B-Cell, Diffuse 50Glioblastoma 49Burkitt Lymphoma 47Urinary Bladder Neoplasms 46Melanoma 45Neuroblastoma 44Hodgkin Disease 44

Interventions

isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Interventional × Gastrointestinal Hemorrhage × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡